CARDIOVASCULAR DISEASE AND COVID-19: WHAT HAS CHANGED?

Yıl 2020, Cilt: 5 Sayı: 2, 99 - 108, 31.10.2020

Özgür Karcıoğlu Mandana Hosseınzadeh Selman Yeniocak Bilgen Özkaya Suleyman Alpar Hüseyin Metin

Öz

Cardiovascular disease (CVD) has long been the leading cause of global morbidity and mortality. However, with the COVID-19 pandemic, which has been the focus of attention all over the world since the end of 2019, this issue has gained a different importance. Presence of CVD leads to more severe COVID-19 and an increased probability of mortality. In addition, both CVD and COVID-19 pave the way to myocardial injury which also boosts the morbidity and death toll. Another point to ponder is possible deprivation of usual healthcare received by cardiac patients (CVD and others) because of the shifted emphasis of hospital and prehospital medical services to COVID-19. As the public can foresee that the pandemics would not disappear rapidly soon, healthcare organization faces a challenge to be redesigned radically. The objective of this article is to analyze CVD, myocardial injury and other cardiac diseases resulting from COVID-19 itself, together with the impact of the pandemics on the usual healthcare of the cardiac patients. 

Anahtar Kelimeler

Cardiovascular Disease, COVID-19, Coronavirus, Acute Myocardial Infarction

Proje Numarası

-

KARDİYOVASKULER HASTALIK VE COVID-19: NE DEĞİŞTİ?

Öz

Kardiyovaskuler hastalık (KVH) dünyada hala morbidite ve mortalitenin önde gelen nedenidir. Ancak 2019 sonundan beri tüm dünyanın ilgi odağı olan COVID-19 pandemisi ile bu konu farklı bir önem kazanmıştır. KVH varlığı COVID-19’un daha şiddetli geçirilmesine ve ölüm olasılığının artmasına yol açmaktadır. KVH dışında da COVID-19 miyokard hasarına yol açmakta ve bu da mortalite ve morbiditeye katkıda bulunmaktadır. Diğer önemli bir nokta ise hem hastane öncesi hem de hastanede sağlık bakımının vurgusu COVID-19’da olduğundan KVH ve diğer kardiyak olgular her zaman alabildikleri bakım düzeyinin uzağında kalmışlardır. Salgının hızla kaybolmayacağı ortaya çıktığından sağlık hizmetlerinde farklı bir organizasyona gidilmesi gerekebilecektir. Bu yazımızda COVID-19 pandemisi koşullarında, hem bu hastalığa bağlı görülebilen KVH, miyokard hasarı ve diğer kardiyak hastalıkları, hem de pandeminin kardiyak hastaların bakım süreçlerine etkisini irdelemeyi amaçladık.

Anahtar Kelimeler

Kardiyovaskuler Hastalık, COVID-19, Coronavirus, Akut Miyokard İnfarktüsü

Destekleyen Kurum

-

Proje Numarası

-

Teşekkür

-

Kaynakça

• Badawi A and Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect Dis. 2016;49:129-133.
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.The Lancet. March 11, 2020. doi: 10.1016/S0140-6736 (20)30566-3. [epub ahead of print].
• Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China. JAMA. 2020; 323: 1061-1069.
• Tam CF, et al. Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on ST-Segment-Elevation Myocardial Infarction Care in Hong Kong, China. Circ Cardiovasc Qual Outcomes. 2020 Mar 17:CIRCOUTCOMES120006631. doi: 10.1161/CIRCOUTCOMES.120.006631. [Epub ahead of print]
• He XW, et al. [Impact of complicated myocardial injury on the clinical outcome of severe or critically ill COVID-19 patients].[Article in Chinese; Abstract available in Chinese from the publisher] Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Mar 15;48(0):E011. doi: 10.3760/cma.j.cn112148-20200228-00137. [Epub ahead of print]
• Guo et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27 : e201017.
• Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol Published online March 25, 2020. doi: 10.1001/jamacardio.2020.0950
• Caforio AL, Pankuweit S, Arbustini E et al (2013) Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J 34(33):2636–2648. https://doi.org/10.1093/eurheartj/eht210(2648a–2648d)
• Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Mar 27. doi: 10.1001/jamacardio.2020.1096. [Epub ahead of print]
• Bansal M. Cardiovascular disease and COVID-19. Diabetes Metab Syndr. 2020 Mar 25; 14(3):247-250.
• Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus Disease 2019 (COVID-19) and Cardiovascular Disease. Circulation. 2020 Mar 21. doi: 10.1161/CIRCULATIONAHA.120.046941. [Epub ahead of print]
• Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the Coronavirus Disease 2019 (COVID-19) Pandemic. J Am Coll Cardiol. 2020 Mar 18. pii: S0735-1097(20)34637-4. doi: 10.1016/j.jacc.2020.03.031. [Epub ahead of print]
• Mahmud E, Dauerman HL, Welt FG, et al. Management of Acute Myocardial Infarction During the COVID-19 Pandemic. Catheter Cardiovasc Interv. 2020 Apr 20. doi: 10.1002/ccd.28946. [Epub ahead of print]
• The European Society for Cardiology. ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-19 Pandemic. https://www.escardio.org/Education/COVID-19-and-Cardiology/ESC-COVID-19-Guidance. (Last update: 28 May 2020)